Corbus Pharmaceuticals
CRBP
107 hedge funds and large institutions have $120M invested in Corbus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 13 closing their positions.
740% more call options, than puts
Call options by funds: $3.94M | Put options by funds: $469K
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
12% more capital invested
Capital invested by funds: $108M → $120M (+$12.6M)
7% more funds holding
Funds holding: 100 → 107 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.12% less ownership
Funds ownership: 75.45% → 72.33% (-3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$3.7M |
| 2 |
O
OrbiMed
New York
|
+$1.18M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$889K |
| 4 |
PAP
Persistent Asset Partners
Hong Kong
|
+$881K |
| 5 |
EAM
Exome Asset Management
New York
|
+$796K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$7.77M |
| 2 |
AC
Armistice Capital
New York
|
-$1.45M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$978K |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$873K |
CRBP Hedge Fund Activity: Q1 2026 in Review
107 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2026, worth a combined $120M — up 12% from $108M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CRBP positions and 13 closed out — a net gain of 11 holders — while 33 added to existing stakes and 22 trimmed.
The largest buyer was Diadema Partners, opening a new position worth an estimated $3.7M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $7.77M sold.
- 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2026, up from 100 in Q4 2025.
- Funds reported $120M of Corbus Pharmaceuticals stock for Q1 2026, up 12% quarter-over-quarter.
- 24 funds opened new Corbus Pharmaceuticals positions in Q1 2026 and 13 closed out, a net change of +11 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2026 was Diadema Partners, an estimated $3.7M added.
- The largest Corbus Pharmaceuticals seller in Q1 2026 was Octagon Capital Advisors, an estimated $7.77M sold.
Based on aggregated 13F filings for Q1 2026.